The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 07, 2021

Filed:

Aug. 01, 2018
Applicant:

Curadigm Sas, Paris, FR;

Inventors:

Marie-Edith Meyre, Saint Mande, FR;

Agnes Pottier, Paris, FR;

Matthieu Germain, Champigny sur Marne, FR;

Celine Berjaud, Paris, FR;

Audrey Darmon, Alfortville, FR;

Assignee:

CURADIGM SAS, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 47/68 (2017.01); A61K 47/42 (2017.01); A61K 9/50 (2006.01); A61K 9/51 (2006.01); C07K 16/22 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6929 (2017.08); A61K 9/5052 (2013.01); A61K 9/51 (2013.01); A61K 9/5169 (2013.01); A61K 47/42 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6931 (2017.08); C07K 16/22 (2013.01);
Abstract

The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody. According to the methods of the invention, administering the biocompatible nanoparticle comprising oligomers of albumin after administering the pharmaceutical compound maintains or increases the therapeutic benefit and reduces toxicity of the pharmaceutical compound when compared to the therapeutic benefit and toxicity induced by administering the pharmaceutical compound alone.


Find Patent Forward Citations

Loading…